Australie - anglais - Department of Health (Therapeutic Goods Administration)

bionomic furniture pty ltd australia - 34982 - cushion, sitting, chair - to support the occupant in the most physiologically efficient upright or seated posture to minimize stress and strain on the human physiology

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

amgrow pty ltd - bacillus thuringiensis subsp. israelensis serotype h14 - aqueous suspension - bacillus thuringiensis subsp. israelensis serotype h14 biological-organism-bt-israele active 0.0 u - insecticide - ditch | flood water | irrigation water | sewage settling pond | stagnant pond | standing water | tidal water saltmarsh | water - - australian house mosquito | brown house mosquito | common australian mosquito | common banded mosquito | domestic container mosquito | mosquito larva | saltmarsh culex | saltmarsh mosquito - larva | aedes notoscriptus | ochlerotatus vigilax

Australie - anglais - Department of Health (Therapeutic Goods Administration)

australian biostain pty ltd - ct215 - biological stain ivds - chemicals, stains and/or solution intended to used specifically as an ivd, either alone or in combination with others for the visualisation of structures and/or other intra/extracellular elements in biological tissues and specimens, including kits and methodology instructions for use such as rapid diff/romanowsky, mycobacterium, kleihauer, trichrome, gram stain kits as may be required within class 2 ct215.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - folic acid, quantity: 5 mg/ml - injection - excipient ingredients: water for injections; sodium hydroxide; disodium edetate - 1. megaloblastic anaemia where the anaemia has been proven to be due to folate deficiency only. 2. prevention of folic acid deficiency in pregnancy and lactation.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - folic acid, quantity: 15 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; disodium edetate - 1. megaloblastic anaemia where the anaemia has been proven to be due to folate deficiency only. 2. prevention of folic acid deficiency in pregnancy and lactation.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 100 mg/ml - injection - excipient ingredients: disodium edetate; benzyl alcohol; water for injections - thiamine hydrochloride injection is used for the prevention and treatment of vitamin b1 deficiency.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 5 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 10 mg/ml; pyridoxine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. patients requiring parenteral b vitamin therapy who cannot tolerate intramuscular injections. 5. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that iv b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 6. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2 and b6. 7. peripheral neuritis caused by vari

Australie - anglais - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 100 mg/ml; riboflavine sodium phosphate, quantity: 2 mg/ml; nicotinamide, quantity: 20 mg/ml; dexpanthenol, quantity: 20 mg/ml; pyridoxine hydrochloride, quantity: 40 mg/ml; cyanocobalamin, quantity: 0.4 mg/ml - injection, solution - excipient ingredients: disodium edetate; benzyl alcohol; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7. carpal tunnel syndrome. 8. pernicious anaemia as a result of in situ b12 deficiency. general indications include: 1. angular stomatitis and glossitis have been shown in some instances to respond to t

Australie - anglais - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 10 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; pyridoxine hydrochloride, quantity: 5 mg/ml; dexpanthenol, quantity: 2.5 mg/ml; nicotinamide, quantity: 25 mg/ml; cyanocobalamin, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 300 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.